Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2017

01-11-2017 | Original Article

The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma

Authors: Ismaheel O. Lawal, Nozipho E. Nyakale, Lerwine M. Harry, Moshe R. Modiselle, Alfred O. Ankrah, Alphonse P. Msomi, Neo P. Mokgoro, Tebatso G. Boshomane, Christophe Van de Wiele, Mike M. Sathekge

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2017

Login to get access

Abstract

Background

To evaluate the impact of HIV infection on tumor burden and therapy outcome following treatment with chemotherapy in patients with Hodgkin lymphoma.

Methods

A total of 136 patients with classical Hodgkin lymphoma were studied (mean age ± SD = 32.31 ± 1.39 years, male = 86, female = 50). Advanced disease (stage III and IV) was present in 64% of patients. HIV infection was present in 57 patients while 79 patients were HIV-negative. Baseline F-18 FDG PET/CT was obtained in all patients. SUVmax, MTV and TLG were determined on the baseline scan to evaluate for tumor burden. All patients completed a standard regimen of adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). After a median period of 8 weeks (range = 6 to 17 weeks), a repeat F-18 FDG PET/CT scan was obtained to evaluate response to therapy using Deauville 5-point scoring system.

Results

The HIV-positive and HIV-negative groups were similar with regards to age and disease stage. The groups were heterogeneous with respect to gender (p = 0.029). The SUVmax, MTV and TLG of lesions were not significant different between the two groups. Complete response was seen in 72.8% of the study population. Presence of HIV infection was associated with higher rate of treatment failure with 40.4% of the HIV-positive patients having treatment failure while only 17.7% of the HIV-negative patients had treatment failure (p = 0.0034). HIV infection was a significant predictor of response to chemotherapy. Effects of SUVmax, MTV, TLG and Ann Arbor stage of the disease were not statistically significant as predictors of therapy outcome. In a multiple logistic regression, presence of HIV infection still remained an independent predictor of therapy outcome in the presence of other factors such as SUVmax, MTV, TLG and the Ann Arbor stage of the disease.

Conclusions

HIV infection is not associated with a higher tumor burden in patients with Hodgkin lymphoma. HIV infection is, however, a strong predictor of poor therapy outcome in patients treated with standard regimen of ABVD.
Literature
1.
go back to reference Spina M, Vaccher E, Carbone A, Tirelli U. Neoplastic complications of HIV infection. Ann Oncol. 1999;10(11):1271–86.CrossRefPubMed Spina M, Vaccher E, Carbone A, Tirelli U. Neoplastic complications of HIV infection. Ann Oncol. 1999;10(11):1271–86.CrossRefPubMed
2.
go back to reference Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2017;12(1):6–11.CrossRefPubMed Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS. 2017;12(1):6–11.CrossRefPubMed
3.
go back to reference Mayor AM, Santiago-Rodriguez EJ, Rios-Olivares E, Tortolero-Luna G, Hunter-Mellado RF. Malignancies trends in a Hispanic cohort of HIV persons in Puerto Rico before and after cART. Int J Cancer Res. 2016;12(2):92–100.CrossRefPubMedPubMedCentral Mayor AM, Santiago-Rodriguez EJ, Rios-Olivares E, Tortolero-Luna G, Hunter-Mellado RF. Malignancies trends in a Hispanic cohort of HIV persons in Puerto Rico before and after cART. Int J Cancer Res. 2016;12(2):92–100.CrossRefPubMedPubMedCentral
4.
go back to reference Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.CrossRefPubMed Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59–67.CrossRefPubMed
5.
go back to reference Spano JP, Poizot-Martin I, Costagliola D, Boué F, Rosmorduc O, Lavolé A, et al. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH working group. Ann Oncol. 2016;27(3):397–401.CrossRefPubMed Spano JP, Poizot-Martin I, Costagliola D, Boué F, Rosmorduc O, Lavolé A, et al. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH working group. Ann Oncol. 2016;27(3):397–401.CrossRefPubMed
8.
go back to reference Barth RE, Tempelman HA, Moraba R, Hoepelman AI. Long-term outcome of an HIV-treatment Programme in rural Africa: viral suppression despite early mortality. AIDS Res Treat. 2011;2011:434375. doi:10.1155/2011/434375.PubMed Barth RE, Tempelman HA, Moraba R, Hoepelman AI. Long-term outcome of an HIV-treatment Programme in rural Africa: viral suppression despite early mortality. AIDS Res Treat. 2011;2011:434375. doi:10.​1155/​2011/​434375.PubMed
9.
go back to reference Bohlius J, Maxwell N, Spoerri A, Wainwright R, Sawry S, Poole J, et al. Incidence of AIDS-defining and other cancers in HIV-positive children in South Africa: record linkage study. Paediatr Infect Dis J. 2016;35(6):e164–70.CrossRef Bohlius J, Maxwell N, Spoerri A, Wainwright R, Sawry S, Poole J, et al. Incidence of AIDS-defining and other cancers in HIV-positive children in South Africa: record linkage study. Paediatr Infect Dis J. 2016;35(6):e164–70.CrossRef
10.
go back to reference Warwick JM, Sathekge MM. PET/CT scanning with a high HIV/AIDS prevalence. Transfus Apher Sci. 2011;44(2):167–72.CrossRefPubMed Warwick JM, Sathekge MM. PET/CT scanning with a high HIV/AIDS prevalence. Transfus Apher Sci. 2011;44(2):167–72.CrossRefPubMed
11.
go back to reference Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and Responsw assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–67.CrossRefPubMedPubMedCentral Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and Responsw assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–67.CrossRefPubMedPubMedCentral
12.
go back to reference Ngeow JYY, Quek RHH, Ng DCE, Hee SW, Tao M, Lim LC, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol. 2009;20(9):1543–7.CrossRefPubMed Ngeow JYY, Quek RHH, Ng DCE, Hee SW, Tao M, Lim LC, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol. 2009;20(9):1543–7.CrossRefPubMed
13.
go back to reference Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A, et al. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40(2):290–301.CrossRefPubMed Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A, et al. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40(2):290–301.CrossRefPubMed
14.
go back to reference Milgrom SA, Dong W, Akhtari M, Smith GL, Pinnix CC, Mawlawi O, et al. Chemotherapy response assessment by FDG-PET-CT in early-stage classical Hodgkin lymphoma: moving beyond the five-point Deauville score. Int J Radiat Oncol Biol Phys. 2017;97(2):333–8.CrossRefPubMed Milgrom SA, Dong W, Akhtari M, Smith GL, Pinnix CC, Mawlawi O, et al. Chemotherapy response assessment by FDG-PET-CT in early-stage classical Hodgkin lymphoma: moving beyond the five-point Deauville score. Int J Radiat Oncol Biol Phys. 2017;97(2):333–8.CrossRefPubMed
15.
go back to reference Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, et al. Posttreatment PET/CT rather than interim PET/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET/CT with conventional imaging. J Nucl Med. 2017;58(4):577–83.CrossRefPubMed Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, et al. Posttreatment PET/CT rather than interim PET/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET/CT with conventional imaging. J Nucl Med. 2017;58(4):577–83.CrossRefPubMed
16.
go back to reference Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, et al. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer. 2015;121(3):423–31.CrossRefPubMed Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, et al. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer. 2015;121(3):423–31.CrossRefPubMed
17.
go back to reference Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30(33):4117–23.CrossRefPubMed Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol. 2012;30(33):4117–23.CrossRefPubMed
18.
go back to reference Sorigué M, Garcia O, Tapia G, Baptista MJ, Moreno M, Mate JL, et al. HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. AIDS. 2017; doi:10.1097/QAD.0000000000001487. Sorigué M, Garcia O, Tapia G, Baptista MJ, Moreno M, Mate JL, et al. HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. AIDS. 2017; doi:10.​1097/​QAD.​0000000000001487​.
19.
go back to reference Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.CrossRefPubMed Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.CrossRefPubMed
20.
go back to reference Lawal I, Lengana T, Ololade K, Boshomane T, Reyneke F, Modiselle M, et al. 18F-FDG PET/CT in the detection of asymptomatic malignant melanoma recurrence. Nuklearmedizin. 2017; doi:10.3413/Nukmed-0864-16-11. Lawal I, Lengana T, Ololade K, Boshomane T, Reyneke F, Modiselle M, et al. 18F-FDG PET/CT in the detection of asymptomatic malignant melanoma recurrence. Nuklearmedizin. 2017; doi:10.​3413/​Nukmed-0864-16-11.
21.
go back to reference Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257–60.CrossRefPubMed Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257–60.CrossRefPubMed
22.
go back to reference Barenguer J, Miralles P, Ribera JM, Rubio R, Valencia E, Mahillo B, et al. Charcateristic and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(2):422–8. Barenguer J, Miralles P, Ribera JM, Rubio R, Valencia E, Mahillo B, et al. Charcateristic and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(2):422–8.
23.
go back to reference Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, et al. Results of treatment with doxorubicin, Bleomycin, vinblastine and Dacarbazine in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Heamatologica. 2007;92(2):191–8.CrossRef Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, et al. Results of treatment with doxorubicin, Bleomycin, vinblastine and Dacarbazine in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Heamatologica. 2007;92(2):191–8.CrossRef
24.
go back to reference Lawal I, Sathekge M. F-18 FDG PET/CT in cardiac and vascular inflammation and infection. Br Med Bull. 2016;120(1):55–74.CrossRefPubMed Lawal I, Sathekge M. F-18 FDG PET/CT in cardiac and vascular inflammation and infection. Br Med Bull. 2016;120(1):55–74.CrossRefPubMed
25.
go back to reference Sathekge M. Differentiation of HIV-associated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry. Eur J Nucl Med Mol Imaging. 2014;41(4):593–5.CrossRefPubMed Sathekge M. Differentiation of HIV-associated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry. Eur J Nucl Med Mol Imaging. 2014;41(4):593–5.CrossRefPubMed
26.
go back to reference Mhlanga JC, Durand D, Tsai HL, Durand CM, Leal JP, Wang H, et al. Differentiation of HIV-associated lymphoma from HIV-associated reactive lymphadenopathy using quantitative PET and symmetry. Eur J Nucl Med Mol Imaging. 2014;41(4):596–604.CrossRefPubMedPubMedCentral Mhlanga JC, Durand D, Tsai HL, Durand CM, Leal JP, Wang H, et al. Differentiation of HIV-associated lymphoma from HIV-associated reactive lymphadenopathy using quantitative PET and symmetry. Eur J Nucl Med Mol Imaging. 2014;41(4):596–604.CrossRefPubMedPubMedCentral
27.
go back to reference Sathekge M, Maes A, Van de Wiele C. FDG-PET in HIV infection and tuberculosis. Semin Nucl Med. 2013;43(5):349–66.CrossRefPubMed Sathekge M, Maes A, Van de Wiele C. FDG-PET in HIV infection and tuberculosis. Semin Nucl Med. 2013;43(5):349–66.CrossRefPubMed
28.
go back to reference Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4(1):5.PubMed Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4(1):5.PubMed
29.
go back to reference Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma using doxorubicin, Bloemycin, Vinblastin, and Dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30(33):4111–6.CrossRefPubMedPubMedCentral Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma using doxorubicin, Bloemycin, Vinblastin, and Dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30(33):4111–6.CrossRefPubMedPubMedCentral
30.
go back to reference Besson C, Lancar R, Prevot S, Brice P, Meyohas MC, Marchou B, et al. High risk features contrast with Favourable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 LYMPHOVIR cohort. Clin Infect Dis. 2015;61(9):1469–75.CrossRefPubMed Besson C, Lancar R, Prevot S, Brice P, Meyohas MC, Marchou B, et al. High risk features contrast with Favourable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 LYMPHOVIR cohort. Clin Infect Dis. 2015;61(9):1469–75.CrossRefPubMed
Metadata
Title
The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma
Authors
Ismaheel O. Lawal
Nozipho E. Nyakale
Lerwine M. Harry
Moshe R. Modiselle
Alfred O. Ankrah
Alphonse P. Msomi
Neo P. Mokgoro
Tebatso G. Boshomane
Christophe Van de Wiele
Mike M. Sathekge
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3766-5

Other articles of this Issue 12/2017

European Journal of Nuclear Medicine and Molecular Imaging 12/2017 Go to the issue